Symbol | Exchange | Currency |
|---|
Sorrento Therapeutics (SRNE) revealed impressive results from an independent real-world study by INMEGEN (The Institute of National Genomics Medicine, Mexico) for the detection of...
Sorrento Therapeutics (SRNE) announces impressive results from an independent study conducted under real-world field conditions by INMEGEN (The Institute of National Genomics...
As a general screening for all-comers (i.e. COVID-19 symptomatic and asymptomatic populations), COVISTIX (n=783) has an 81% sensitivity vs. 62% (n=2202) sensitivity by globally...
We’re well into the second half of 2021, and with any luck at all we’ll soon see last year’s major headwinds fully relegated to the rear-view mirror. Even so, current
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday...
Sorrento Therapeutics, Inc. (SRNE) is a clinical-stage biopharmaceutical company developing new cancer treatment therapies. It’s also developing potential antiviral th...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.325 | 4.50 | 4.40 | +0.125 | +2.98% | 3.82M | London | |||
| 0.1375 | 0.00 | 0.00 | 0.0000 | 0.00% | 69.21M | London | |||
| 10.80 | 11.00 | 11.00 | -0.25 | -2.26% | 2.83M | London | |||
| 578.00 | 584.40 | 573.80 | -5.20 | -0.89% | 1.32M | London | |||
| 27.00 | 26.00 | 26.00 | -0.7500 | -2.70% | 554.47K | London | |||
| 4,495.00 | 4,535.00 | 4,480.00 | -58.0 | -1.27% | 165.05K | London | |||
| 132.50 | 134.22 | 126.82 | +5.56 | +4.38% | 72.52M | London | |||
| 2.75 | 2.75 | 2.75 | 0.00 | 0.00% | 76.39K | London | |||
| 16.30 | 16.70 | 16.30 | +0.050 | +0.30% | 8.18M | London | |||
| 432.80 | 443.00 | 428.40 | +2.80 | +0.65% | 2.48M | London | |||
| 680.60 | 685.40 | 644.80 | +26.80 | +4.10% | 5.89M | London | |||
| 0.875 | 0.00 | 0.00 | 0.0000 | 0.00% | 2.53M | London | |||
| 0.93 | 0.00 | 0.00 | 0.00 | 0.00% | 497.30K | London | |||
| 991.00 | 998.40 | 988.00 | -6.00 | -0.60% | 1.57M | London | |||
| 1,578.00 | 1,601.50 | 1,570.00 | -27.00 | -1.68% | 802.25K | London |
Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.